MET and neoplasm: Driver mutations in EGFR, MET, BRAF and TP53 were almost always clonal; heterogeneous driver alterations occurring later during tumor evolution were observed in 76% of the tumors and were more common in PIK3CA and NF1 genes and in genes involved in chromatin modification and DNA damage response and repair.